Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03300947 · ClinicalTrials.gov registry record · Phase 1
Psilocybin for Treatment of Obsessive Compulsive Disorder
A Phase 1 study, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03300947 is a Phase 1 study that has completed, run by University of Arizona. The registered enrollment target is 15 participants.
The verdict
NCT03300947, a Phase 1 study, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study will evaluate whether psilocybin, a hallucinogenic drug, improves symptoms of obsessive compulsive disorder (OCD), whether it is safely tolerated as treatment of OCD, and will investigate the mechanisms by which it works.
Interventions
- DRUG Psilocybin 100 mcg/kg
- DRUG Psilocybin 300 mcg/kg
- DRUG Lorazepam 1 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-01-02 |
| Est. Completion | 2023-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03300947
The ClinicalTrials.gov registry entry for NCT03300947 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Psilocybin 100 mcg/kg is the first listed.
NCT03300947 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03300947 about?
NCT03300947 is a clinical study titled "Psilocybin for Treatment of Obsessive Compulsive Disorder". This study will evaluate whether psilocybin, a hallucinogenic drug, improves symptoms of obsessive compulsive disorder (OCD), whether it is safely tolerated as treatment of OCD, and will investigate the mechanisms by which it works.
What is the current status of trial NCT03300947?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2019-01-02. Estimated completion is 2023-12-30.
What interventions are being tested in trial NCT03300947?
The interventions under investigation include: Psilocybin 100 mcg/kg (DRUG), Psilocybin 300 mcg/kg (DRUG), Lorazepam 1 mg (DRUG).
Who is sponsoring clinical trial NCT03300947?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.